mRNA-1283

DB22668ApprovedInvestigationalVaccines

mRNA-1283 is an mRNA vaccine encoding the N-terminal and receptor-binding domains of the spike protein of SARS-CoV-2 Omicron variant lineage JN.1. It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.

Mechanism: mRNA-1283 is a nucleoside-modified mRNA, encapsulated in lipid nanoparticles, encoding the N-terminal domain and the receptor-binding domain of the spike protein of SARS-CoV-2 Omicron variant JN.1. The administration of mRNA-1283 elicits an immune response against the SARS-CoV-2 spike protein which provides protection against COVID-19.
Curator reviewed · 1 reference
Primary indication: mRNA-1283 - as the primary ingredient in mNEXSPIKE - is indicated for active immunization against COVID-19 caused by SARS-CoV-2 in patients who have been previously vaccinated and who are ≥65 years of age or 12-64...Curator reviewed · 2 structured indications
Code names: mRNA-1283

What you can answer from here — as of December 10, 2025

290Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as mRNA-1283, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account